#United States #Pittsburgh #Foundation Fighting Blindness #FAM161A #Eye & Ear Foundation

Foundation Fighting Blindness and Eye & Ear Foundation Collaboration

In a significant step towards understanding inherited retinal diseases (IRDs), the Foundation Fighting Blindness has announced a partnership with the Eye & Ear Foundation of Pittsburgh. This collaboration will add a new cohort focusing on individuals with IRDs linked to mutations in the FAM161A gene to the Foundation’s Uni-Rare Natural History Study. The initiative is expected to shed light on disease progression and inform future clinical trial designs for emerging therapies.

The Uni-Rare Natural History Study aims to catalog the natural history of various IRDs and bring together a wealth of data that can improve therapeutic approaches. Mutations in the FAM161A gene account for roughly 1-2% of autosomal recessive retinitis pigmentosa (RP) cases in North America and up to 12% in certain Middle Eastern populations. Despite growing interest, there is a lack of comprehensive longitudinal data on how FAM161A-related RP progresses, which this new study cohort aims to address.

The Importance of the FAM161A Cohort

The newly established cohort is designed to track participants for four years, providing essential information on the natural progression of FAM161A-related retinal degeneration. This data is critical for understanding the disease and establishing accurate endpoints for potential clinical trials. Dr. Todd Durham, Senior Vice President for Clinical and Outcomes Research at the Foundation Fighting Blindness, emphasized the significance of having robust natural history data, stating that clinical trials launching for therapies targeting FAM161A will benefit significantly from a clearer understanding of the disease's progression.

Dr. José-Alain Sahel, a distinguished professor at the University of Pittsburgh and a key figure in this collaboration, remarked that understanding the progression of FAM161A-related retinitis pigmentosa is crucial as new therapies emerge. The insights gained from this cohort will contribute to more effective clinical trial designs, ensuring that therapies can reach patients more quickly.

The Role of Rare Ventures™

The funding for this cohort will stem from Rare Ventures™, a pioneering venture philanthropy platform initiated to expedite the development of therapies and cures for rare diseases. Launched in August 2026, Rare Ventures™ aims to create an integrated approach that encompasses scientific discovery, patient data management, and resource allocation to advance therapeutic development actively.

Michael Hund, founder of Rare Ventures™, noted that this partnership is a pivotal example of how collaborative efforts can lead to significant advancements in the realm of clinical research and therapy development for rare diseases.

Enrollment and Participation

Individuals with FAM161A-related retinal disease, alongside their healthcare providers, are encouraged to learn more about their eligibility for the Uni-Rare study. Information regarding enrollment and eligibility can be accessed through ClinicalTrials.gov (NCT05589714) or by visiting the Foundation Fighting Blindness website.

The collaborative nature of this project showcases how partnerships can effectively address the complex challenges surrounding rare diseases. The Foundation Fighting Blindness has continuously aimed to accelerate research efforts to provide effective treatments, directly impacting those affected by retinal degenerative diseases.

About the Organizations

Established in 1971, the Foundation Fighting Blindness is a leading advocate in the global race to develop treatments and cures for blinding diseases. To date, nearly $1 billion has been raised to further research aimed at developing solutions for conditions such as retinitis pigmentosa and related disorders. The Eye & Ear Foundation of Pittsburgh supports the Departments of Ophthalmology and Otolaryngology at the University of Pittsburgh, contributing to advancements in patient care and academic research.

Through this collaboration, both organizations aim to make significant strides in understanding and ultimately treating FAM161A-related retinal diseases, illustrating a committed partnership towards improving patient outcomes and accelerating medical advancements in this field.